TransEnterix Announces Senhance Robotic System Program At Imperial College London And Imperial College Healthcare NHS Trust

TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics to improve minimally invasive surgery, today announced that it has installed a Senhance™ Robotic Surgical System in partnership with Imperial College London and St. Mary's Hospital of the Imperial College Healthcare NHS Trust.

"Imperial College London and the Imperial College Healthcare NHS Trust are among the leading centers for minimally invasive surgical innovation in the world," said Todd M. Pope, President and CEO at TransEnterix. "We are delighted that they have chosen to add the Senhance system to their MIS program in general and colorectal surgery."

"We are pleased to be the first center in the UK to use this new robotic technology," said Professor Lord Ara Darzi, The Paul Hamlyn Chair of Surgery at Imperial College London. "Our centre thrives on combining promising technology with our skilled consultant surgical team to advance the field of minimally invasive surgery and we look forward to developing this program together."

The Senhance is the first surgical system that brings haptic force feedback, eye-sensing camera control, and responsible economics through reusable instrumentation to robotics.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options. The company is focused on the commercialization of the Senhance Surgical Robotic System, a multi-port robotic system that brings the advantages of robotic surgery to patients while enabling surgeons with innovative technology such as haptic feedback and eye sensing camera control. The company is also developing the SurgiBot™ System, a single-port, robotically enhanced laparoscopic surgical platform. The Senhance Surgical Robotic System has been granted a CE Mark but is not currently available for sale in the United States. For more information, visit the TransEnterix website at

Forward-Looking Statements

This press release includes statements relating to the Senhance™ Surgical Robotic System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether our Senhance Robotic System Program with Imperial College will provide to be successful. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 3, 2016 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on

Copyright Business Wire 2010